Discover trends, market shifts, and competitive outlooks for the actemra (tocilizumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Projected Market Size and Growth Rates for the Actemra (Tocilizumab) Market From 2025 To 2029?
In recent times, the market size of actemra (tocilizumab) has seen a swift expansion. From a valuation of $5,160 million in 2024, it is projected to escalate to $5,710 million in 2025, with a compound annual growth rate (CAGR) of 10.7%. The historic growth can be linked to an increasing incidence of autoimmune diseases, expanding use of biologic treatments, heightened awareness of chronic inflammatory states, robust regulatory endorsements in important markets, and the growth of healthcare infrastructure in more developed regions.
Anticipated to surge in the coming years, the market size for Actemra (Tocilizumab) is predicted to reach $8,480 million by 2029, with a Compound Annual Growth Rate (CAGR) of 10.4%. Several factors are contributing to this growth in the forecast period including the broadening of therapeutic applications like COVID-19 cytokine release syndrome, an increased interest in personalized medicine, the development and acceptance of biosimilars, escalating health expenditure in emerging markets, and a heightened awareness of biologic therapies in growing areas. The forecast period is also expected to see the rise of certain trends such as the increased usage of subcutaneous formulations, a heightened emphasis on the development of biosimilars for cost reduction, advancements in biotechnology leading to better drug delivery systems, ongoing clinical trials for new therapeutic indications and strategic collaborations and financing by pharmaceutical firms.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19849&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Actemra (Tocilizumab) Market?
An increase in the incidence of rheumatoid arthritis is predicted to stimulate the growth of the actemra (tocilizumab) market in the future. Rheumatoid arthritis is a long-term autoimmune disease which causes inflammation in joints, damage, and diminishes the quality of life and it impacts millions of people worldwide. Various factors such as smoking, obesity, environmental exposure, and hormonal elements affect run the risk of rheumatoid arthritis. Actemra (tocilizumab) is a remedy utilized to decrease inflammation and hinder joint destruction by blocking the interleukin-6 (IL-6) receptor, predominantly in patients who have not responded to other treatments. For example, based on figures released by the National Institute for Health and Care Research (NIHR), a government organization in the UK, around 700,000 individuals in the UK had rheumatoid arthritis as of April 2024. Additionally, in June 2024, a study by the Australian Institute of Health and Welfare, a national agency in Australia, reported that an estimated 514,000 people (2.0% of the populace) in Australia had rheumatoid arthritis in 2022. In 2023, the ailment represented 2.0% of the total disease pressure and 16% of the ailment load for musculoskeletal conditions. Rheumatoid arthritis was also associated with 1,322 fatalities in 2022, which amounted to 5.1 deaths per 100,000 inhabitants and constituted 0.7% of overall deaths. Consequently, the increasing incidence of rheumatoid arthritis is a key driver for the actemra (tocilizumab) market.
Which Key Market Segments Comprise the Actemra (Tocilizumab) Market and Drive Its Revenue Growth?
The actemra (tocilizumab)market covered in this report is segmented –
1) By Product Type: Min Purity Less Than 98%; Min Purity 98%-99%; Min Purity More Than 99%
2) By Dosage: Injection; Solution; Concentrate
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By Application: Cytokine Release Syndrome (CRS); Systemic Juvenile Idiopathic Arthritis (sJIA); Giant Cell Arteritis (GCA); Rheumatoid Arthritis (RA)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=19849&type=smp
Which Areas Are Leading Regions in the Actemra (Tocilizumab) Market Expansion Across the Globe?
North America was the largest region in the actemra (Tocilizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Actemra (Tocilizumab) Market Over the Coming Years?
The primary trend in the Actemra (tocilizumab) market is the emphasis on creating innovative solutions like tocilizumab biosimilar in order to maintain a competitive advantage in the sector. Tocilizumab biosimilars, which are approved for the treatment of autoimmune diseases and COVID-19, provide an alternative to the original drug, Actemra. A case in point is the launch of Tyenne, the inaugural tocilizumab biosimilar referencing RoActemra (tocilizumab), by the Germany-based healthcare company, Fresenius Kabi, in November 2023 in the European Union. Tyenne is sanctioned for the treatment of a variety of inflammatory and immune diseases, such as rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and COVID-19.
View the full report here:
https://www.thebusinessresearchcompany.com/report/actemra-tocilizumab-global-market-report
How Is the Actemra (Tocilizumab) Market Conceptually Defined?
Actemra (Tocilizumab) is a prescription biologic medication classified as an interleukin-6 (IL-6) receptor antagonist, used to treat various autoimmune and inflammatory conditions. It works by inhibiting IL-6, a cytokine involved in inflammation, helping to reduce symptoms and prevent disease progression in conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19849
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
